Key regions: Germany, United States, India, Japan, United Kingdom
Lesotho, a small landlocked country in Southern Africa, has a developing healthcare system that is facing several challenges. Among these challenges is the prevalence of rheumatic diseases, which has led to an increasing demand for anti-rheumatic drugs in the country.
Customer preferences: The majority of the population in Lesotho relies on public healthcare facilities, which often have limited resources and inadequate medication supplies. As a result, patients with rheumatic diseases may face difficulty in accessing the necessary medication. However, there is a growing awareness of the importance of managing rheumatic diseases, and patients are increasingly seeking treatment options.
Trends in the market: The market for anti-rheumatic drugs in Lesotho is growing, driven by an increase in the prevalence of rheumatic diseases and a growing demand for treatment options. However, the market is still relatively small, and there is a limited range of drugs available. The market is dominated by generic drugs, which are more affordable for patients, but may have lower efficacy and safety profiles compared to branded drugs.
Local special circumstances: Lesotho's healthcare system is facing several challenges, including a shortage of healthcare workers, inadequate infrastructure, and limited funding. These challenges may affect the availability and affordability of anti-rheumatic drugs in the country. Additionally, Lesotho's high altitude and cold climate may exacerbate rheumatic symptoms, further increasing the demand for treatment options.
Underlying macroeconomic factors: Lesotho is a low-income country with a small economy, heavily reliant on the export of diamonds and textiles. The country's healthcare system is largely funded by external aid, which may limit the government's ability to invest in healthcare infrastructure and medication supplies. Additionally, Lesotho has a high prevalence of HIV/AIDS, which may increase the risk of developing rheumatic diseases and further strain the healthcare system.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
